Pfizer, Gilead in Agreement to Manufacture Remdesivir for Covid-19
August 07 2020 - 9:16AM
Dow Jones News
By Michael Dabaie
Pfizer Inc. said Friday it is in multi-year agreement with
Gilead Sciences Inc. to manufacture remdesivir for treatment of
Covid-19
Pfizer said the deal is to manufacture and supply Gilead's
investigational antiviral remdesivir, as one of multiple external
manufacturing organizations supporting efforts to scale up supply
of the investigational treatment for Covid-19.
Pfizer will provide contract manufacturing services at its
McPherson, Kan., facility.
"From the beginning it was clear that no one company or
innovation would be able to bring an end to the COVID-19 crisis.
Pfizer's agreement with Gilead is an excellent example of members
of the innovation ecosystem working together to deliver medical
solutions," said Pfizer Chief Executive Albert Bourla.
Gilead shares were up 1% premarket, to $69.47, while Pfizer
shares were up 1%, to $38.60.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
August 07, 2020 09:01 ET (13:01 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024
